Stock DNA
Pharmaceuticals & Biotechnology
USD 300 Million (Micro Cap)
14.00
NA
0.00%
-0.28
7.75%
1.54
Total Returns (Price + Dividend) 
Tactile Systems Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Tactile Systems Technology Hits New 52-Week High of $23.84
Tactile Systems Technology, Inc. achieved a new 52-week high of USD 23.84 on November 4, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, with a favorable price-to-earnings ratio and effective financial management.
Read MoreIs Tactile Systems Technology, Inc. overvalued or undervalued?
As of 17 October 2025, Tactile Systems Technology, Inc. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, with a P/E ratio of 14, a Price to Book Value of 1.14, and an EV to EBITDA of 6.49. In comparison, CareDx, Inc. is rated very attractive with a significantly lower P/E ratio of -27.91, while Organogenesis Holdings, Inc. is considered risky with a P/E ratio of 608.59, highlighting the relative valuation challenges Tactile faces. Despite a recent positive performance with a 1-week return of 2.18% compared to the S&P 500's 1.70%, the year-to-date return of -15.18% against the S&P 500's 13.30% suggests that Tactile is struggling to keep pace with broader market trends. Overall, the combination of its valuation ratios and peer comparisons indicates that Tactile Systems Technology, Inc. is currently overvalued....
Read More
Tactile Systems Technology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Tactile Systems Technology, Inc. has recently adjusted its valuation, with its stock price at $14.53. Over the past year, it has returned 1.96%, underperforming the S&P 500. Key metrics include a P/E ratio of 14 and a ROCE of 13.69%, reflecting its operational efficiency amid a competitive industry landscape.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 71 Schemes (36.91%)
Held by 71 Foreign Institutions (11.19%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 7.79% vs 7.17% in Jun 2024
YoY Growth in quarter ended Jun 2025 is -25.58% vs 4,400.00% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 6.78% vs 11.18% in Dec 2023
YoY Growth in year ended Dec 2024 is -40.35% vs 259.22% in Dec 2023






